DUBLIN--(BUSINESS WIRE)--The "Global Stroke Diagnostics and Therapeutics Market Analysis 2019" report has been added to ResearchAndMarkets.com's offering.
The Global Stroke Diagnostics and Therapeutics market is expected to reach $49,698.98 million by 2026 growing at a CAGR of 7.9% during 2018 to 2026.
Stroke refers to the brain attack. Stroke occurs when the supply of blood to the brain is either interrupted or reduced. In this condition, the brain does not get enough oxygen or nutrients which cause the brain cells to die.
Factors such as technological advancement, growing aging population, and people suffering from diabetes are favouring the market. On the other hand, increasing health expenditure, hypertension and also increasing tobacco users are also fuelling the market. However factors such as unfavourable reimbursement scenario and high cost of treatments are hampering the market growth.
Haemorrhagic Stroke is caused on account of the arteries in the brain either leaking blood or bursting open. When it happens, blood collects in the brain tissue. This is toxic for the brain tissue causing the cells in that area to weaken and die. It is one among the cause of death and a leading cause of serious, long-term disability across the world.
Key Questions Answered in this Report:
- How this market evolved since the year 2016
- Market size estimations, forecasts and CAGR for all the segments presented in the scope
- Key Market Developments and financials of the key players
- Opportunity Analysis for the new entrants
- SWOT Analysis of the key players
- Fastest growing markets analysed during the forecast period
Key Topics Covered:
1 Market Synopsis
2 Research Outline
2.1 Research Snapshot
2.2 Research Methodology
2.3 Research Sources
3 Market Dynamics
3.1 Drivers
3.2 Restraints
4 Market Environment
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Stroke Diagnostics and Therapeutics Market, By Application
5.1 Introduction
5.2 Ischemic Stroke
5.3 Haemorrhagic Stroke
6 Global Stroke Diagnostics and Therapeutics Market, By Diagnostics
6.1 Introduction
6.2 Carotid Ultrasound
6.3 Cerebral Angiography
6.4 Computed Tomography Scan (CT scan)
6.5 Electrocardiography
6.6 Magnetic Resonance Imaging (MRI)
7 Global Stroke Diagnostics and Therapeutics Market, By Therapeutics
7.1 Introduction
7.2 Anticoagulant
7.3 Antihypertensive
7.4 Antiplatelet
7.5 Tissue Plasminogen Activator
8 Global Stroke Diagnostics and Therapeutics Market, By Geography
8.1 Introduction
8.2 North America
8.3 Europe
8.4 Asia Pacific
8.5 South America
8.6 Middle East & Africa
9 Strategic Benchmarking
10 Vendors Landscape
10.1 Abbott Laboratories
10.2 B. Braun Melsungen AG
10.3 Bayer AG
10.4 Boston Scientific Corporation
10.5 Cardinal Health
10.6 Cordis Corporation
10.7 GE Healthcare
10.8 Genentech Inc
10.9 Koninklijke Philips N.V.
10.10 Medtronic plc
10.11 Merck & Co Inc
10.12 Merck Sharp & Dohme Corp
10.13 Siemens AG
10.14 Stryker Corporation
10.15 Teleflex Inc
For more information about this report visit https://www.researchandmarkets.com/research/bf6q4f/global_stroke?w=4
